ATN-161
Based on 11 publication(s) in Google Scholar
ATN-161 is an antagonist of α5β1 integrin and αvβ3 integrin, as well as an inhibitor of fibrosis, an inhibitor of oxidative stress, a tight junction stabilizer, a mitochondrial integrity protector, an angiogenesis inhibitor and an antiviral agent. ATN-161 inhibits NLRP3, MAPK, and ROS. ATN-161 protects mice from SARS-CoV-2 infection. ATN-161 reduces infarct volume, alleviates edema, decreases immune cell infiltration, reduces the area of choroidal neovascularization lesions, lowers tumor microvessel density and viral load. ATN-161 can be used in research related to ischemic stroke, choroidal neovascularization, breast cancer, coronavirus disease 2019 (COVID-19), and liver metastasis of colorectal cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.50%
- CAS 番号: 262438-43-7
- 分子式: C23H35N9O8S
- 分子量:597.64
-
保管条件:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 ATN-161
More- Cancer Cell. 2019 Jan 14;35(1):64-80.e7. [Abstract]
- Nat Nanotechnol. 2026 Jun;21(6):880-891. [Abstract]
- ACS Nano. 2025 Jun 10;19(22):20564-20577. [Abstract]
- J Adv Res. 2025 May 25:S2090-1232(25)00370-4. [Abstract]
- Stem Cell Res Ther. 2022 Jul 18;13(1):327. [Abstract]
- Cell Prolif. 2021 Apr;54(4):e13012. [Abstract]
- Sci Signal. 2022 Dec 6;15(763):eabn2743. [Abstract]
- ACS Biomater Sci Eng. 2023 May 8;9(5):2524-2533. [Abstract]
- Colloids Surf B Biointerfaces. 2022 Feb:210:112227. [Abstract]
- J Cell Sci. 2025 Dec 1;138(23):jcs264412. [Abstract]
- Res Sq. 2025 Dec 17.
Customer Validation & Images
-
Cell Imaging/Staining
-
RT-PCR
-
Flow Cytometry
-
Flow Cytometry
生物活性
|
α5β1 |
αvβ3 |
NLRP3 |
ATN-161 (5-25 μM; 1 h) significantly inhibits the upregulation of NLRP3 inflammasome induced by OGD/R in bEnd.3 cells[1].
ATN-161 (pretreatment for 1 h, oxygen-glucose deprivation for 6 h + reoxygenation for 24 h, 10 μM) significantly inhibits oxidative stress in bEnd.3 cells induced by oxygen-glucose deprivation/reoxygenation (OGD/R), including mitochondrial superoxide anion production and intracellular ROS generation[1].
ATN-161 (10 μM) inhibits the VEGF-induced upregulation of integrin α5-β1 expression in human choroidal endothelial cells (hCEC)[2].
ATN-161 (1 nM-100 μM; 30 min) inhibits VEGF-induced migration of human choroidal endothelial cells (hCEC) in a dose-dependent manner, with a significant effect observed starting at the concentration of 100 nM[2].
ATN-161 (1 nM-100 μM; 24 h) does not inhibit VEGF-induced proliferation of human choroidal endothelial cells (hCEC)[2].
ATN-161 competes with the biotinylated analog ATN-453 for binding to purified human integrin α5β1 and αvβ3, which is confirmed by the specific high-affinity binding of ATN-453 to these integrins[3].
ATN-161 (1-1000 μM) increases the survival rate of VeroE6 cells infected with SARS-CoV-2, with a minimum effective concentration of only 1 μM, and the survival rate peaks at 10 μM[4].
ATN-161 (1.0 μM; 48 h) significantly reduces the viability and proliferation capacity of human umbilical vein endothelial cells (HUVEC) by 21% after 48 hours of incubation on fibronectin-coated culture plates under low-serum conditions, while exerting no effect on CT26 mouse colon cancer cells[5].
ATN-161 (1-100 μM; up to 5 days) exerts no significant effect on the proliferation of MDA-MB-231 breast cancer cells during 5 days of in vitro culture[3].
ATN-161 (20 μM; 30 min) significantly inhibits the level of phosphorylated MAPK in MDA-MB-231 breast cancer cells in vitro, but has no effect on the levels of FAK or phosphorylated FAK[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human choroidal endothelial cells (hCECs)
-
Concentration:1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM
-
Incubation Time:24 h
-
Result:Did not alter VEGF-induced proliferation at any tested concentration.
-
Cell Line:human choroidal endothelial cells (hCECs)
-
Concentration:1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 100 μM
-
Incubation Time:30-minute preincubation, followed by 8-hour migration
-
Result:Reduced VEGF-induced migration in a dose-dependent manner starting at 100 nM, with significant inhibition observed at 100 nM, 1 μM, 10 μM, and 100 μM (P < 0.001 vs.
VEGF-only group).
-
Cell Line:human MDA-MB-231 breast cancer cells
-
Concentration:1-100 μmol/L
-
Incubation Time:up to 5 days
-
Result:Showed no significant effect on MDA-MB-231 cell proliferation compared to vehicle-treated controls over 5 days.
-
Cell Line:human umbilical vein endothelial cells (HUVEC), CT26 murine colon cancer cells
-
Concentration:1.0 μM
-
Incubation Time:48 h
-
Result:Reduced HUVEC number by 21% compared to control (p < 0.03).
Exhibited no significant effect on CT26 murine colon cancer cell number.
ATN-161 (0.1-10 μg/mL; intravitreal injection; single dose administered immediately after laser photocoagulation) inhibits laser-induced choroidal neovascularization (CNV) in Brown-Norway rats in a dose-dependent manner. At the dose of 10 μg/mL, it reduces the average CNV leakage score to 0.7, the average CNV area to 12186 μm2, and the average CNV thickness to 72.3 μm (all *P* < 0.001 compared with the sham-operated group), while also decreasing VEGF expression levels on postoperative days 7, 10, and 14[2].
ATN-161 protects k18-hACE2 transgenic mice from SARS-CoV-2 infection[1].
ATN-161 inhibits VEGF-induced retinal neovascularization in mice by targeting integrin α5β1 and the NLRP3 inflammasome[1].
ATN-161 (0.05-1 mg/kg; intravenous injection; three times per week; for 6 consecutive weeks) induces dose-dependent, statistically significant inhibition of subcutaneous breast cancer xenograft growth in female BALB/c nu/nu mice, with maximal efficacy observed at doses of 0.1 mg/kg and 1 mg/kg, while reducing tumor angiogenesis, cell proliferation levels, and the expression of P-MAPK[3].
ATN-161 (100 mg/kg; i.p.; once every 3 days; administered starting on day 4 after tumor cell injection) alone reduces tumor microvessel density by 48% in a mouse model of colorectal cancer liver metastasis. When combined with continuously infused 5-FU (HY-90006), it significantly reduces liver tumor burden, number of metastatic lesions, and tumor cell proliferation, increases the apoptosis rate, and improves mouse survival (p < 0.03)[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Brown-Norway (BN) (12-week-old male, 200 to 250 g, laser-induced choroidal neovascularization)[2]
-
Dosage:0.1 μg/mL; 10 μg/mL
-
Administration:intravitreal injection; single dose immediately after laser photocoagulation
-
Result:Reduced mean CNV leakage score to 1.1, mean CNV area to 16,890 μm2, and mean CNV thickness to 81.3 μm at 0.1 μg/mL dose on day 14 (P < 0.001 vs. sham for leakage score and area, P < 0.05 vs. sham for thickness).
Reduced mean CNV leakage score to 0.7, mean CNV area to 12,186 μm2, and mean CNV thickness to 72.3 μm at 10 μg/mL dose on day 14 (all P < 0.001 vs. sham).
Lowered VEGF levels in RPE-choroid complexes on days 7, 10, and 14 compared to sham group (P < 0.001).
Showed remarkable reduction of CNV thickness on days 7 and 14, with less evident fluorescein leakage at day 14 relative to sham-injected eyes at 10 μg/mL dose.
-
Animal Model:BALB/c nu/nu (5-week-old, 15-20 g, female, subcutaneous xenograft of MDA-MB-231 human breast cancer cells)[3]
-
Dosage:0.05 mg/kg; 0.1 mg/kg; 1 mg/kg
-
Administration:i.v.; thrice a week; 6 weeks
-
Result:Caused a dose-dependent reduction in tumor volume compared to vehicle controls.
Produced marked, statistically significant tumor volume reduction at 0.1 and 1 mg/kg doses with no significant difference in efficacy between these two doses.
Reduced tumor microvessel density by 43% at 1 mg/kg dose.
Significantly decreased tumor cell mitotic index at 1 mg/kg dose.
Significantly reduced Ki-67 proliferation index at 1 mg/kg dose.
Decreased expression of phosphorylated mitogen-activated protein kinase (P-MAPK) in tumor tissue at 1 mg/kg dose.
Left levels of focal adhesion kinase (FAK) and phosphorylated FAK (P-FAK) unchanged at 1 mg/kg dose.
Caused no significant weight loss in treated animals, indicating good tolerability.
-
Animal Model:BALB/c (8-week-old male; induced by 10,000 CT26 murine colon carcinoma cells injected into spleens)[5]
-
Dosage:100 mg/kg (monotherapy); 100 mg/kg + 100 mg/kg/2 weeks 5-FU (combination)
-
Administration:i.p.; every third day; starting day 4 after tumor cell injection; continuous infusion (5-FU, 2 weeks)
-
Result:Reduced microvessel density in liver metastases by 48% compared to controls (p < 0.03).
Did not significantly reduce liver weight, number of liver metastases, tumor cell proliferation, increase tumor cell apoptosis, or improve survival when administered alone.
Significantly reduced liver weight (p < 0.02), number of liver metastases (p < 0.05), tumor cell proliferation (p < 0.01), reduced microvessel density by 44% compared to controls (p < 0.03), increased tumor cell apoptosis (p < 0.03), and improved overall survival (p < 0.03, log-rank test) relative to single-agent treatments when combined with continuous-infusion 5-FU.
Left six mice alive and healthy on day 21 when the experiment was terminated.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 262438-43-7
-
性状 Solid
-
分子量 597.64
-
分子式 C23H35N9O8S
-
Color White to off-white
-
SMILES
O=C(N)C[C@@H](C(N)=O)NC([C@H](CS)NC([C@H](CO)NC([C@H](CC1=CNC=N1)NC([C@H]2N(C(C)=O)CCC2)=O)=O)=O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling. [Abstract]2019 Jan 14;35(1):64-80.e7. PMID: 30612941 -
Nat Nanotechnol
2026 Jun;21(6):880-891. PMID: 42286217 -
ACS Nano
Deciphering the Distinct Roles of Molecular and Supramolecular Chirality in Osteogenic Differentiation of Mesenchymal Stem Cells in 3D Hydrogels. [Abstract]2025 Jun 10;19(22):20564-20577. PMID: 40425514 -
J Adv Res
Fibrinogen exacerbates α-synuclein aggregation and mitochondrial dysfunction via alpha5beta3 integrin in Parkinson's disease. [Abstract]2025 May 25:S2090-1232(25)00370-4. PMID: 40425084 -
Stem Cell Res Ther
Extracellular matrix derived from Wharton's Jelly-derived mesenchymal stem cells promotes angiogenesis via integrin αVβ3/c-Myc/P300/VEGF. [Abstract]2022 Jul 18;13(1):327. PMID: 35851415
ATN-161 purchased from MedChemExpress. Usage Cited in: Stem Cell Res Ther. 2022 Jul 18;13(1):327. [Abstract]
ATN-161 trifluoroacetate salt (8 h) and ECM significantly inhibited the tube formation ability but did not change the tube formation ability of HUVECs.
-
Cell Prolif
Vitronectin-activated αvβ3 and αvβ5 integrin signalling specifies haematopoietic fate in human pluripotent stem cells. [Abstract]2021 Apr;54(4):e13012. PMID: 33656760
ATN-161 purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2021 Apr;54(4):e13012. [Abstract]
ATN-161 trifluoroacetate salt (10 μM; from day 2 to day 6) did not affect the mRNA expression of RUNX1, GATA2 and MYB in hPSCs.
ATN-161 purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2021 Apr;54(4):e13012. [Abstract]
ATN-161 trifluoroacetate salt (10 μM; from day 2 to day 6) did not affect the production of CD43+ HPCs in VTN‐coated hPSCs.
ATN-161 purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2021 Apr;54(4):e13012. [Abstract]
ATN-161 trifluoroacetate salt (10 μM; from day 2 to day 6) did not affect the production of CD43+ HPCs in VTN‐coated hPSCs.
-
Sci Signal
Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension. [Abstract]2022 Dec 6;15(763):eabn2743. PMID: 36473049 -
ACS Biomater Sci Eng
Regulation of Macrophage Polarization on Chiral Potential Distribution of CFO/P(VDF-TrFE) Films. [Abstract]2023 May 8;9(5):2524-2533. PMID: 37092816 -
Colloids Surf B Biointerfaces
Anisotropic magneto-mechanical stimulation on collagen coatings to accelerate osteogenesis. [Abstract]2022 Feb:210:112227. PMID: 34838419 -
J Cell Sci
Bile canaliculi formation in primary hepatocytes requires α1β1 integrin-dependent adherens junction re-organization. [Abstract]2025 Dec 1;138(23):jcs264412. PMID: 41347643 -
溶剤 & 溶解度
DMSO : 25 mg/mL (41.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 5 mg/mL (8.37 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (292 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Amruta N, et al. ATN-161 Ameliorates Ischemia/Reperfusion-induced Oxidative Stress, Fibro-inflammation, Mitochondrial damage, and Apoptosis-mediated Tight Junction Disruption in bEnd.3 Cells. Inflammation. 2021 Dec;44(6):2377-2394. [Content Brief]
[2]. Wang W, et al. The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo. Invest Ophthalmol Vis Sci. 2011 Sep 14;52(10):7213-20. [Content Brief]
[3]. Khalili P, et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Molecular cancer therapeutics. 2006 Sep;5(9):2271-80. [Content Brief]
[4]. Beddingfield BJ, et al. The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection. JACC Basic Transl Sci. 2021 Jan;6(1):1-8. [Content Brief]
[5]. Stoeltzing O, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. International journal of cancer. 2003 Apr 20;104(4):496-503. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.6732 mL | 8.3662 mL | 16.7325 mL | 41.8312 mL |
| 5 mM | 0.3346 mL | 1.6732 mL | 3.3465 mL | 8.3662 mL | |
| DMSO | 10 mM | 0.1673 mL | 0.8366 mL | 1.6732 mL | 4.1831 mL |
| 15 mM | 0.1115 mL | 0.5577 mL | 1.1155 mL | 2.7887 mL | |
| 20 mM | 0.0837 mL | 0.4183 mL | 0.8366 mL | 2.0916 mL | |
| 25 mM | 0.0669 mL | 0.3346 mL | 0.6693 mL | 1.6732 mL | |
| 30 mM | 0.0558 mL | 0.2789 mL | 0.5577 mL | 1.3944 mL | |
| 40 mM | 0.0418 mL | 0.2092 mL | 0.4183 mL | 1.0458 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
ATN-161 関連分類
HY-13535 関連分類
Powered by Bioz
- ATN-161
- 262438-43-7
- ATN161
- ATN 161
- Integrin
- Apoptosis
- NOD-like Receptor (NLR)
- p38 MAPK
- Reactive Oxygen Species (ROS)
- SARS-CoV
- α5β1 integrin
- bEnd.3 cells
- ischemic stroke
- SARS-CoV-2
- colorectal liver metastases
- αvβ3 integrin
- choroidal neovascularization
- human choroidal endothelial cells
- VeroE6 cells
- MDA-MB-231 breast cancer cells
- Inhibitor
- inhibitor
- inhibit